Our Partners

Internal Collaborators

Manisha Balwani, MD, MS

Manisha Balwani, MD, MS

Genetics and Genomics

Emily J. Gallagher, MD

Emily J. Gallagher, MD

Endocrine, Diabetes and Bone Diseases

Bruce D. Gelb, MD

Bruce D. Gelb, MD

Pediatrics

Carol R. Horowitz, MD

Carol R. Horowitz, MD

Internal Medicine

Amy Kontorovich, MD

Amy Kontorovich, MD

Cardiovascular Disease

Matthew A. Levin, MD

Matthew A. Levin, MD

Anesthesiology

Ruth Loos, PhD

Ruth Loos, PhD

Environmental Medicine & Public Health

Aimee Lucas, MD

Aimee Lucas, MD

Gastroenterology

External Collaborators

Kathleen Carole Barnes

Kathleen Carole Barnes

University of Colorado Denver - Anschutz Medical Campus

Toby Bloom

Toby Bloom

New York Genome Center

Esteban G. Burchard, MD, MPH

Esteban G. Burchard, MD, MPH

University of California, San Francisco

Carlos Bustamante

Carlos Bustamante

Stanford University

Christopher Gignoux

Christopher Gignoux

University of Colorado Denver - Anschutz Medical Campus

John M. Greally, Ph.D., M.B.,B.Ch.

John M. Greally, Ph.D., M.B.,B.Ch.

Albert Einstein College of Medicine

Rasika Ann Mathias, Sc.D.

Rasika Ann Mathias, Sc.D.

The Johns Hopkins University

Melissa P. Wasserstein, M.D.

Melissa P. Wasserstein, M.D.

Albert Einstein College of Medicine

Genevieve Wojcik

Genevieve Wojcik

Stanford University

Noah Zaitlen, PhD

Noah Zaitlen, PhD

University of California, San Francisco

GenomicsFirst Committee

 
The GenomicsFirst Committee is a team of internal experts in genomic medicine at Mount Sinai. This committee was established to guide efforts in the development and use of genomic screening in clinical care across the Mount Sinai Health System.
 

Members

George Diaz, MD, PhD

George Diaz, MD, PhD

Chief, Division of Medical Genetics, Department of Genetics and Genomic Sciences

Randi Zinberg, MS, CGC

Randi Zinberg, MS, CGC

Director, Master of Science Program in Genetic Counseling

Aimee Lucas, MD, MS

Aimee Lucas, MD, MS

Associate Professor, Henry D. Janowitz Division of Gastroenterology, Department of Medicine

Amy Kontorovich, MD, PhD

Amy Kontorovich, MD, PhD

Medical Director, Adult Cardiovascular Genetics, Zena and Michael A. Wiener Cardiovascular Institute

Internal Stakeholders

Charles Bronfman Institute for Personalized Medicine

 
The Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai is driving innovation in the data-driven and gene-based individualization of health care.

Learn more »

BioMe

 
Funded by The Charles Bronfman Institute for Personalized Medicine, BioMe is an electronic medical record-linked biobank that enables researchers to quickly and efficiently conduct genetic, epidemiologic, molecular, and genomic studies on large collections of research specimens linked with medical information.

Learn more »

Icahn Institute for Data Science and Genomic Technology

 
At the Icahn Institute, our vision is to transform biomedical research and healthcare delivery into a data-driven, evidence-based, patient-tailored discipline. Our research program focuses on harnessing huge molecular datasets to address complex diseases, using advanced biotechnologies to rapidly test novel treatments tailored to each patient, and bringing these treatments to benefit patients faster than has ever been possible.

Learn more »

Department of Medicine

 
The Department of Medicine is at the forefront of twenty-first century medicine with an uncompromising commitment to providing excellent patient care; to conducting cutting-edge research; and to the rigorous training of tomorrow’s physicians and physician-scientists.

Learn more »

INGH

 
We are building a new model for translational biomedical research enabled by new technologies and the changing landscape of healthcare.

Learn more »

Department of Genetics and Genomic Sciences

 
At the Department of Genetics and Genomic Sciences, our research and clinical teams work together to translate research insights to improve patient diagnostics and treatment.

We are committed to precision medicine, tailoring treatments to our patient’s specific needs. We’re able to achieve such personalized results by classifying patients into subpopulations based on their susceptibility to a particular disease or response to a particular treatment.

Learn more »

External Partners

Sema4

 
Sema4® is a patient-centered predictive health company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease.

Learn more »

New York Genome Center

 
The New York Genome Center (NYGC) is an independent, nonprofit academic research institution focused on furthering genomic research that leads to scientific advances and new insights and therapies for patients with neurodegenerative diseases, neuropsychiatric diseases, and cancer, leveraging our strengths in whole genome sequencing, genomic analysis, and development of genomic tools.

Learn more »